Cargando…

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database

INTRODUCTION: Two‐drug regimens (2‐DR) have the potential to be a viable solution to the challenges of treatment complexity, cost, adverse effects and contraindications. We sought to describe the real‐world use and effectiveness of 2‐DR among persons living with HIV (PLHIV) in the United States. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pierone, Gerald, Henegar, Cassidy, Fusco, Jennifer, Vannappagari, Vani, Aboud, Michael, Ragone, Leigh, Fusco, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893210/ https://www.ncbi.nlm.nih.gov/pubmed/31802641 http://dx.doi.org/10.1002/jia2.25418

Ejemplares similares

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes
por: Hsu, Ricky K., et al.
Publicado: (2023)

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)

978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV
por: Mounzer, Karam, et al.
Publicado: (2019)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study
por: Mounzer, Karam, et al.
Publicado: (2019)

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022)

Antiretroviral therapy and liver disorders in the OPERA(®) cohort
por: Wohlfeiler, Michael, et al.
Publicado: (2020)

886. The Impact of the COVID-19 Pandemic on Clinical Follow-Up, Monitoring and Regimen Discontinuation for People Living with HIV in the US
por: Pierone, Gerald, et al.
Publicado: (2021)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

936. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
por: Lackey, Philip, et al.
Publicado: (2018)

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
por: Sension, Michael, et al.
Publicado: (2023)

1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
por: Yan, Lei, et al.
Publicado: (2022)

1023. Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability
por: Pierone, Gerald, et al.
Publicado: (2023)

341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States
por: Hsu, Ricky, et al.
Publicado: (2019)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA(®) Cohort
por: Hsu, Ricky K, et al.
Publicado: (2023)

74. Maternal Dolutegravir (DTG) Use During Pregnancy and Birth Outcomes: The Antiretroviral Pregnancy Registry (APR)
por: Vannappagari, Vani, et al.
Publicado: (2021)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
por: Vilaplana, Vicente Escudero, et al.
Publicado: (2010)

Psychiatric Symptoms in Patients Receiving Dolutegravir
por: Fettiplace, Anna, et al.
Publicado: (2017)

Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy–Experienced Ugandans With Virologic Failure
por: Mpoza, Edward, et al.
Publicado: (2019)

Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials
por: Nan, Cassandra, et al.
Publicado: (2017)

Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens
por: Rhee, Soo-Yon, et al.
Publicado: (2020)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda
por: Billioux, Alexander, et al.
Publicado: (2015)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

Benchmarking HIV Quality Measures in the US OPERA HIV Cohort
por: Heglar, Robert, et al.
Publicado: (2019)

2085. PrEP Interest and Preferences Among US Black and Hispanic Men – A National Survey
por: Poteat, Tonia, et al.
Publicado: (2022)

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice
por: Potard, Valérie, et al.
Publicado: (2015)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

Prevalence of and risk for gastrointestinal bleeding and peptic ulcerative disorders in a cohort of HIV patients from a U.S. healthcare claims database
por: Bratton, Emily, et al.
Publicado: (2017)

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa
por: Tchounga, Boris K., et al.
Publicado: (2020)

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
por: Llibre, Josep M, et al.
Publicado: (2022)

1549. Risk Factors, Risk Perception, and Long-acting PrEP Awareness and Interest among US Women: A National Survey
por: Poteat, Tonia, et al.
Publicado: (2023)

Fitness Cost of Antiretroviral Drug Resistance Mutations on the pol Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological Failure
por: Hunter, James R., et al.
Publicado: (2021)

2502. Impact of Pharmacist-Led Antiretroviral Therapy Simplification Initiative in Heavily Treatment-Experienced Patients on Virologic Control
por: Jimenez, Humberto R, et al.
Publicado: (2019)

Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials
por: Berhan, Asres, et al.
Publicado: (2013)

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study
por: Gagliardini, Roberta, et al.
Publicado: (2018)

Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system
por: T. Tchakoute, Christophe, et al.
Publicado: (2022)

557. Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV-Infected Patients
por: Maki, Gina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4cdbgl6k9pelv8qqobo6c38d27